Skip to main content
Clinical Trials/NCT03875053
NCT03875053WithdrawnNot Applicable

Evaluation of Obstructive Sleep Apnea in Head and Neck Cancer

Barbara Ann Karmanos Cancer Institute1 site in 1 countryStarted: July 25, 2023Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Withdrawn
Locations
1
Primary Endpoint
Obstructive sleep apnea (OSA) rate before and after chemoradiation therapy (CRT) in stage III-IVb patients undergoing CRT

Study Overview

Brief Summary

This trial studies information from a home sleep apnea machine to evaluate obstructive sleep apnea in patients with stage III-IV head and neck cancer. Sleep apnea (trouble breathing during sleep) can occur in head and neck cancer patients who have swelling in their neck. Wearing a sleep apnea machine overnight may help doctors evaluate obstructive sleep apnea in patients with head and neck cancer.

Detailed Description

This is a single center study in HNSCC subjects to assess the effects of CRT on OSA.. Patients will be screened with a physical exam and questionnaire (The Berlin questionnaire, STOP-BANG, PSQI) and when eligible, will have the home sleep study (Specific aim 1). The low risk group (based on the physical exam and questionnaire) with stage IVc will not be eligible for the home sleep study and will concentrate on palliation of their symptoms. For locally advanced HNSCC patients undergoing definitive CRT, post CRT home sleep study results will also be assessed (Specific aim 2). When the patient is diagnosed with OSA based on the home sleep study, or if the home sleep study is negative but if the patient had high risks based on the screening process, the patient will be referred to the sleep medicine clinic. If life-threatening obstructive sleep apnea is found, the patient will be referred to sleep medicine clinic right away and will be taken off study. Otherwise, the patients will prioritize their definitive CRT for HNSCC, and will be referred to sleep medicine clinic once CRT has been completed.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Locally advanced (stage III-IVb) and metastatic (stage IVc) HNSCC who are referred to medical oncology. Patients may not have received upfront definitive surgical resection of the primary tumor or upfront neck dissection.
  • •Patients must be able to operate the home sleep study device.
  • •Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

Exclusion Criteria

  • •Patients should not have received any prior systemic chemotherapy or radiation therapy for locally advanced or metastatic HNSCC.
  • •Patients with tracheostomy or those requiring the assistance of a ventilator will be ineligible for the study.

Arms & Interventions

Monitoring device, Quality of Life Assessment, Questionnaire

Experimental

Patients wear the home sleep apnea machine overnight. Patients undergoing standard of care CRT wear the home sleep apnea machine a second time 3 months after completion of CRT.

Intervention: Monitoring Device (Diagnostic Test)

Monitoring device, Quality of Life Assessment, Questionnaire

Experimental

Patients wear the home sleep apnea machine overnight. Patients undergoing standard of care CRT wear the home sleep apnea machine a second time 3 months after completion of CRT.

Intervention: Quality-of-Life Assessment (Other)

Monitoring device, Quality of Life Assessment, Questionnaire

Experimental

Patients wear the home sleep apnea machine overnight. Patients undergoing standard of care CRT wear the home sleep apnea machine a second time 3 months after completion of CRT.

Intervention: Questionnaire Administration (Other)

Outcomes

Primary Outcomes

Obstructive sleep apnea (OSA) rate before and after chemoradiation therapy (CRT) in stage III-IVb patients undergoing CRT

Time Frame: Up to 1 year

The definition of OSA will be defined as apnea-hypopnea index of \> 5 for both pre and post CRT. The OSA rate is the proportion of patients diagnosed with OSA. Will be assessed using a two-sided McNemar test based on the OSA occurrence (Yes versus \[vs.\] No) for each patient. The OSA rates pre and post CRT will be described by means and their two-sided confidence intervals (Cls). The univariable and multivariable conditional logistic regression models will be further used for the primary objective with patients' baseline characteristics as covariates.

Secondary Outcomes

  • Response to CRT(Up to 1 year)
  • Occurrence of OSA in stage III-IVb patients undergoing CRT(Up to 1 year)
  • OSA rate in locally advanced or metastatic stage head and neck squamous cell carcinoma (HNSCC) patients(Up to 1 year)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Ammar Sukari

Principal Investigator

Barbara Ann Karmanos Cancer Institute

Study Sites (1)

Loading locations...

Similar Trials